2011-02-07 18:32:23 UTC

Rifaximin Improves Driving in Hepatic Encephalopathy

Feb. 7, 2011

Doctors found that in patients with cirrhosis and minimal hepatic encephalopathy, driving performance significantly improved after treatment with rifaximin.

Patients with cirrhosis and minimal hepatic encephalopathy have driving difficulties, but the effects of therapy on driving performance are unclear. In a study appearing in Gastroenterology, doctors concluded that patients with minimal hepatic encephalopathy significantly improve driving simulator performance after treatment with rifaximin, compared with placebo.

Gastroenterology; 2011: 140(2): 478-87

More on Cirrhosis

Blog: Special 15th Anniversary Collection from Clinical Gastroenterology and Hepatology

Oct. 11, 2017

Celebrate this milestone with a look back at landmark articles, commentaries and reviews. Read more on the AGA Journals blog.

Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis

Oct. 11, 2017

Statin use is probably associated with lower risk of hepatic decompensation and mortality, and might reduce portal hypertension, in patients with CLDs.

Cirrhosis Presenting as Cutaneous Calciphylaxis

Oct. 11, 2017

A 73-year-old woman with a history of hypertension presented with a 3-month history of a painful, non-healing right calf ulcer and 2–3 weeks of painful, dusky purple patches on the right thigh.